PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS

Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant and platelet antiaggregant drugs are used amo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Iván F. PALOMO G, Constanza I. TORRES U., Rodrigo E. MOORE-Carrasco., Marcelo A. ALARCÓN L., Patricio J. MARAGAÑO L.
Formato:	article
Lenguaje:	EN
Publicado:	Universidad de Antioquia 2009
Materias:	platelet antiaggregants cardiovascular diseases Food processing and manufacture TP368-456 Pharmaceutical industry HD9665-9675
Acceso en línea:	https://doaj.org/article/31500303069f477ca93935deba6ecb97
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31500303069f477ca93935deba6ecb97
record_format	dspace
spelling	oai:doaj.org-article:31500303069f477ca93935deba6ecb972021-11-19T04:16:03ZPLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS0121-40042145-2660https://doaj.org/article/31500303069f477ca93935deba6ecb972009-05-01T00:00:00Zhttps://revistas.udea.edu.co/index.php/vitae/article/view/1435https://doaj.org/toc/0121-4004https://doaj.org/toc/2145-2660Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant and platelet antiaggregant drugs are used among others. Due to the participation of platelets, not only in the early stages of the atherogenesis but also in the artery thromboses, the use of platelet antiaggregant drugs is very relevant in the primary and secondary prevention of the artery thrombosis. In this review, after a brief description of the primary hemostasis, aspects of antiplatelet like mechanisms of action and use asocied risks during the last 10 years are adressed. Primarily literature source was www.pubmed.com. The terms used in the search were: platelet antiaggregant, aspirin, dipyridamole, clopidogrel, abciximab, among others, then we searched the full texts of articles of interest and also used some hematology books. Iván F. PALOMO GConstanza I. TORRES U.Rodrigo E. MOORE-Carrasco.Marcelo A. ALARCÓN L.Patricio J. MARAGAÑO L.Universidad de Antioquiaarticleplatelet antiaggregantscardiovascular diseasesFood processing and manufactureTP368-456Pharmaceutical industryHD9665-9675ENVitae, Vol 16, Iss 1 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	platelet antiaggregants cardiovascular diseases Food processing and manufacture TP368-456 Pharmaceutical industry HD9665-9675
spellingShingle	platelet antiaggregants cardiovascular diseases Food processing and manufacture TP368-456 Pharmaceutical industry HD9665-9675 Iván F. PALOMO G Constanza I. TORRES U. Rodrigo E. MOORE-Carrasco. Marcelo A. ALARCÓN L. Patricio J. MARAGAÑO L. PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS
description	Cardiovascular diseases are the main cause of death in the world. Next to efforts to reduce the cardiovascular risk factors, several drugs are resorted to decrease morbimortality associated to these diseases: antihypertensive, antidiabetic, hypolipemiant and platelet antiaggregant drugs are used among others. Due to the participation of platelets, not only in the early stages of the atherogenesis but also in the artery thromboses, the use of platelet antiaggregant drugs is very relevant in the primary and secondary prevention of the artery thrombosis. In this review, after a brief description of the primary hemostasis, aspects of antiplatelet like mechanisms of action and use asocied risks during the last 10 years are adressed. Primarily literature source was www.pubmed.com. The terms used in the search were: platelet antiaggregant, aspirin, dipyridamole, clopidogrel, abciximab, among others, then we searched the full texts of articles of interest and also used some hematology books.
format	article
author	Iván F. PALOMO G Constanza I. TORRES U. Rodrigo E. MOORE-Carrasco. Marcelo A. ALARCÓN L. Patricio J. MARAGAÑO L.
author_facet	Iván F. PALOMO G Constanza I. TORRES U. Rodrigo E. MOORE-Carrasco. Marcelo A. ALARCÓN L. Patricio J. MARAGAÑO L.
author_sort	Iván F. PALOMO G
title	PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS
title_short	PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS
title_full	PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS
title_fullStr	PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS
title_full_unstemmed	PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS
title_sort	platelet antiaggregants: mechanisms of action and use asocied risks
publisher	Universidad de Antioquia
publishDate	2009
url	https://doaj.org/article/31500303069f477ca93935deba6ecb97
work_keys_str_mv	AT ivanfpalomog plateletantiaggregantsmechanismsofactionanduseasociedrisks AT constanzaitorresu plateletantiaggregantsmechanismsofactionanduseasociedrisks AT rodrigoemoorecarrasco plateletantiaggregantsmechanismsofactionanduseasociedrisks AT marceloaalarconl plateletantiaggregantsmechanismsofactionanduseasociedrisks AT patriciojmaraganol plateletantiaggregantsmechanismsofactionanduseasociedrisks
_version_	1718420453405491200

PLATELET ANTIAGGREGANTS: MECHANISMS OF ACTION AND USE ASOCIED RISKS

Ejemplares similares